Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 1

Status

Active not recruiting 3Completed 1

Sponsor Class

OTHER 6INDUSTRY 4NETWORK 3

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Breast Neoplasms 13Glioblastoma 10Glioma 7Astrocytoma 6Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 4Neoplasms 4Brain Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Stomach Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Oligodendroglioma 2Melanoma 2Carcinoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Diseases 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Seroma 1Rectal Neoplasms 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Patient Preference 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Inflammatory Breast Neoplasms 1

Interventions

pembrolizumab 40Gemcitabine 37Cisplatin 28Carboplatin 17enfortumab vedotin 15Nivolumab 15Mitomycin 14atezolizumab 13avelumab 12Docetaxel 10vinflunine 95-aminolevulinic acid hexyl ester 9apaziquone 8Paclitaxel 8BCG Vaccine 7durvalumab 6Fluorouracil 6Cystectomy 6sacituzumab govitecan 4Surgical Procedures, Operative 4Drug Therapy 4vofatamab 3valrubicin 3tisotumab vedotin 3erdafitinib 3cemiplimab 3belinostat 3Therapeutic Uses 3Ramucirumab 3Cystoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Neoplasms × Surgical Procedures, Operative × Clear all
NCT04700124 2026-02-05

KEYNOTE-B15

Merck Sharp & Dohme LLC

Phase 3 Completed
808 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT06305767 2026-01-13

INTerpath-005

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
230 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03924856 2025-08-28

KEYNOTE-866

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
907 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03924895 2025-08-28

KEYNOTE-905

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
595 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡